Article Correctness Is Author's Responsibility: What would it take to make FMT mainstream? Two publications consider the opportunities

(Cell Press) Fecal microbiota transplant treatment for most microbiome-associated diseases has not been rigorously studied in humans--and any such studies would be subject to regulation by the Food and Drug Administration. In a pair of forums publishing February 12 in the journal Cell Host & Microbe, clinicians and an FDA scientist detail some areas of FMT research that could facilitate the development of safe and effective FMT therapies for patients.